Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01629667 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 409
- Enrollment target
NCT01629667: Clinical Trial Phase 2 study, sponsored by MedImmune.
NCT01629667 is a Phase 2 study that was terminated before completion, run by MedImmune. The registered enrollment target is 409 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (208% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01629667, a Phase 2 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 409 participants
- Enrollment target
Study Summary
To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.
Primary Outcome
Forced vital capacity (FVC) is a standard pulmonary function test used to monitor disease progression in IPF. FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in litres. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) \* 100%.
Interventions
- OTHER Placebo
- BIOLOGICAL Tralokinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Why NCT01629667 stopped before completion
NCT01629667 is an interventional study that assigns participants to a tested intervention. The registered 409 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (208% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01629667 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01629667 about?
NCT01629667 is a clinical study titled "A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis". To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.
What is the current status of trial NCT01629667?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 409 participants. The study started on 2012-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01629667?
The interventions under investigation include: Placebo (OTHER), Tralokinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01629667?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01629667's enrollment target sits among peer trials
409 93rd of 2000 higher than 1,908 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717334 · 409 participants
A Study of Lung Cancer Screening in People With Unexplained Weight Loss
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia